Figure 1.
Cell surface immune checkpoint expression. Expression on HSCs (CD3−, CD11b−, CD14−, CD34+, CD38−), HPCs (CD3−CD11b−, CD14−, CD34+, CD38+), G-MDSCs (CD3−, CD33+, CD38−, CD11b+, CD14−), erythroid (CD3-, CD71+), and CD33+ cells was determined by flow cytometry. (A) PDL1 expression in TP53 mutant (Mut) vs wild-type (WT) myeloid populations. (B) Representative dot plot of increased PDL1 expression in TP53 mutant HSCs. (C) PD-1 expression TP53 mutant vs wild-type myeloid populations. (D) PDL1 expression in HSCs and HPCs based on HMA treatment status. g-MDSCs, granulocytic myeloid-derived suppressor cells. **P ≤ .01, ****P < .0001.

Cell surface immune checkpoint expression. Expression on HSCs (CD3−, CD11b−, CD14−, CD34+, CD38−), HPCs (CD3−CD11b−, CD14−, CD34+, CD38+), G-MDSCs (CD3−, CD33+, CD38−, CD11b+, CD14−), erythroid (CD3-, CD71+), and CD33+ cells was determined by flow cytometry. (A) PDL1 expression in TP53 mutant (Mut) vs wild-type (WT) myeloid populations. (B) Representative dot plot of increased PDL1 expression in TP53 mutant HSCs. (C) PD-1 expression TP53 mutant vs wild-type myeloid populations. (D) PDL1 expression in HSCs and HPCs based on HMA treatment status. g-MDSCs, granulocytic myeloid-derived suppressor cells. **P ≤ .01, ****P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal